Low molecular weight heparin (LMWH), exerts its action mostly by antithrombin mediated inhibition of factor Xa. But some thrombin inhibition by low molecular weight heparin is retained and is of importance for the antithrombotic effect.

Prevention of venous thromboembolism in surgical patients, prevention of extra-corporeal thrombosis during haemodialysis, pulmonary embolism.

LMWH have higher bioavailability after SC injection than standard, heparin. LMWH binds less than heparin to plasma proteins. The clearance of LMWH is mainly renal, independent of dose and slower than metabolic clearance of heparin. 

Major bleeding disorder, active peptic ulcer, hemorrhagic stroke, acute bacterial endocarditic, drug induced thrombocytopenia.

Thrombocytopenia, haemorrhage, injection site ecchymoses, osteoporosis, sensitivity phenomenon.

Hepatic, renal impairment, history of CI ulceration, uncontrolled hypertension.

  
General  Surgery :
3500 I.U. S.C. 2 hours before surgery followed by 3500 I.U. once daily for 7-10 days.

Orthopaedic  Surgery :
50 I.U. / kg body weight S.C. 2 hours before surgery followed by 2500 I.U. once daily for 7-10 days.
In patients below 40kg and above 100kg dose should be individualised.

1ml amp.  2500  anti-xa I.U. /ml
2ml amp.  5000  anti-xa I.U./2ml
(5 amps  per box)  
  
  

  
*  for the use of a registered Medical practitioner or a Hospital or a Laboratory only.

[Go Back to the Export product list]

Disclaimer : This guide is provided for information purposes only, and for use of a registered medical practitioner or a hospital or a laboratory only. The authors, webmaster, or respective references / links are no way responsible for the content of the information. Although a concerted effort has been made to ensure the validity of the information contained in this document, we give no assurance for the accuracy of the information in this documents.